SCHEMBL23326510

SCHEMBL23326510

CC(=O)Nc1cc(C(F)(F)F)cc(C(=O)O)c1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN5 P54829 1/20 0.50
MPO P05164 1/20 0.46
CYP2C19 P33261 3/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
AKR1C3 P42330 2/20 0.44
AKR1C2 P52895 2/20 0.44
GPR35 Q9HC97 3/20 0.43
KDM4E B2RXH2 2/20 0.43
HSD17B10 Q99714 2/20 0.43
RXFP1 Q9HBX9 1/20 0.43
ALDH1A1 P00352 2/20 0.42
TAS2R14 Q9NYV8 3/20 0.42
GRIK1 P39086 1/20 0.41
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
USP2 O75604 1/20 0.40
HPGD P15428 1/20 0.40
SORT1 Q99523 1/20 0.40
CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29861499 1.00 PTPN5 (0.50) PTPN5MPOCYP2C19CYP1A2CYP2C9
SCHEMBL23326539 0.89 PTPN5 (0.51) PTPN5MPOCYP2C19CYP1A2CYP2C9
SCHEMBL23326784 0.80 PTPN5 (0.44) PTPN5MPOCYP2C19CYP1A2CYP2C9
SCHEMBL29861148 0.80 PTPN5 (0.44) PTPN5MPOCYP2C19CYP1A2CYP2C9
SCHEMBL3885198 0.79 KDM4E (0.59) MPOCYP2C19CYP1A2CYP2C9AKR1C3
SCHEMBL11323055 0.79 GRIK1 (0.62) MPOCYP2C19CYP1A2CYP2C9KDM4E
SCHEMBL23345280 0.77 PTPN5 (0.49) PTPN5CYP2C19CYP1A2CYP2C9GPR35
SCHEMBL9465049 0.75 TAS2R14 (0.43) MPOCYP2C19AKR1C3AKR1C2GPR35
SCHEMBL31697325 0.75 TAS2R14 (0.43) MPOCYP2C19AKR1C3AKR1C2GPR35
SCHEMBL9465832 0.74 ALDH1A1 (0.46) MPOCYP2C19CYP1A2AKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4620531-A2 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. (US) 2025-09-24 EP disclosed
US-12258366-B2 Bicyclic heteroaryl compounds and uses thereof Revolution Medicines, Inc. (US) 2025-03-25 US disclosed
US-20230365605-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-11-16 US disclosed
US-20230365605-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-11-16 US disclosed
CN-116425742-A Bicyclic heteroaryl compounds and uses thereof 锐新医药公司 2023-07-14 CN disclosed
EP-4055017-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. (US) 2022-09-14 EP disclosed
CN-114901662-A Bicyclic heteroaryl compounds and uses thereof 锐新医药公司 2022-08-12 CN disclosed
US-11168102-B1 Bicyclic heteroaryl compounds and uses thereof Revolution Medicines, Inc. (US) 2021-11-09 US disclosed
US-11168102-B1 Bicyclic heteroaryl compounds and uses thereof Revolution Medicines, Inc. (US) 2021-11-09 US disclosed
US-20210139517-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. 2021-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11168102-B1 Bicyclic heteroaryl compounds and uses thereof SOS1, SOST, SOS2 PTPN5 442/4885MPO 4851/4885CYP2C19 3214/4885
US-20230365605-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF SOST, SOS1, SOS2 PTPN5 883/4885MPO 4797/4885CYP2C19 3440/4885
US-20210139517-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF SOST, SOS1, SOS2 PTPN5 883/4885MPO 4797/4885CYP2C19 3440/4885
US-12258366-B2 Bicyclic heteroaryl compounds and uses thereof SOST, SOS1, SOS2 PTPN5 883/4885MPO 4797/4885CYP2C19 3440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.